SCHEMBL28021603

SCHEMBL28021603

CCCCOC(=O)c1cc(Nc2cc(C)n[nH]2)nc(S(=O)(=O)c2ccc(NC(=O)CC)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GLA P06280 1/20 0.42
▸ CA12 O43570 5/20 0.40
▸ CA1 P00915 5/20 0.40
▸ CA2 P00918 5/20 0.40
▸ CA9 Q16790 5/20 0.40
▸ ATM Q13315 1/20 0.40
▸ AURKA O14965 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ SLC2A1 P11166 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ TP53 P04637 2/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204669 0.83 AURKB (0.55) ALDH1A1AURKAAURKB
SCHEMBL28021678 0.82 ATM (0.45) ALDH1A1KMT2AGLACA12CA1
SCHEMBL28021626 0.81 ATM (0.46) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL28021591 0.79 AURKB (0.51) ALDH1A1KMT2AATMAURKAAURKB
SCHEMBL2204784 0.72 AURKB (0.60) ALDH1A1AURKAAURKBMAPT
SCHEMBL28022078 0.71 PKM (0.44) ALDH1A1KMT2ACA1CA2AURKA
SCHEMBL12430844 0.70 AURKB (0.70) AURKAAURKB
SCHEMBL28565368 0.70 AURKB (0.44) ALDH1A1KMT2ACA12CA1CA2
SCHEMBL28022116 0.70 ADORA1 (0.47) ALDH1A1KMT2AAURKAAURKBMAPT
SCHEMBL28570313 0.70 KMT2A (0.37) ALDH1A1KMT2AAURKAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112755193-A Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof 德玛医药 2021-05-07 — — CN disclosed
CN-104797267-A Method of treating tyrosine kinase inhibitor-resistant malignancies in patients with genetic polymorphism or AHI1 dysregulation or mutation using dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof DEL MAR PHARMACEUTICALS 2015-07-22 — — CN disclosed
Send feedback